Design and development of Candesartan cilexetil emulsomal drug delivery systems for the effective management of cardiovascular diseases
Journal Title: Indian Journal of Research in Pharmacy and Biotechnology - Year 2014, Vol 2, Issue 4
Abstract
The main objective of this research work was to formulate candesartan cilexetil emulsomes (AT2 receptor antagonist) for percutaneous administration for sustaining the drug release and reducing the particle size up to nanolevel leading to better therapy. The compatibility studies of candesartan cilexetil, Glyceryl behenate (Campritol), Soyalecithin and the physical mixture were conducted using I.R spectroscopy. The results revealed that the peaks obtained for candesartan cilexetil pure samples and physical mixture were to be compatible and without changes in the functionalities indicating their compatibility. Candesartan cilexetil emulsomes were formulated by varying the concentrations of glyceryl behenate (0.25-1.0%) and Phosphatidylcholine (0.3-1.6%) by employing thin film hydration technique followed by emulsification followed and high speed homogenization. The formulations were found to be reproducible. When subjected to evaluation, formulation F6 possessed the maximum entrapment efficiency. In-vitro permeation studies of candesartan cilexetil emulsomes revealed that the drug release from all the formulations followed First-order kinetics and ascertained peppas mechanism & F5, F6 and F7 ascertained higuchi’s mechanism respectively. Application of Korsmeyer-peppas equation to the data of all the formulations revealed that the mechanism of candesartan cilexetil emulsomes was governed by predominant non-Fickian diffusion and case –II transport. The average particle size rage of optimized formulation was found to be 116.4 nm well within the emulsomal range. The zeta potential value of the optimized formulation was found to be -27.5 mv indicating high negative surface change leading to greater stability. Based on the above statement the formulation F6 was considered as better formulation for the effective management of cardiovascular diseases.
Authors and Affiliations
Malla Vasavi Chandrika, Medarametla Kishore Babu
Keywords
Related Articles
- EP ID EP33235
- DOI -
- Views 286
- Downloads 0
Eagle’s syndrome – An alarming elongation
The name styloid process (SP) was derived from the Greek word ‘stylos’ meaning a pillar. It is a bony, cylindrical, needle-shaped projection, which originates from the posterior-inferior side of the petrous bone, immed...
A REVIEW ON MEDICINAL PLANTS HAVING ANTIOXIDANT POTENTIAL
Natural compounds from plants and other life forms (bacteria, fungi, marine organisms) represent a major source of molecules with medicinal properties. Among them, antioxidant substances are of particular interest. The...
DEVELOPMENT AND EVALUATION OF HIGH POROUS MOUTH DISSOLVING TABLETS CONTAINING LAMOTRIGINE COMPLEXATION
Lamotrigine (LMG) is an Antiepileptic drug which is widely used in epilepsy. It is also used in simple and complex partial seizures and secondary generalized tonic-clonic seizures. It is poorly water soluble drug (0.17...
DIABETES EPIDEMIC IN INDIA: RISK FACTORS, SYMPTOMS AND TREATMENT
Diabetes is a metabolism disorder in which the pancreas in the human body fails to produce insulin, or is unable to use the insulin produced in an effective manner. Most of the food we eat is broken into glucose, which...
AN OVERVIEW ABOUT PHARMACY EDUCATION IN INDIA
If the current trend toward automation continues, there will be severe cuts in the employment of pharmacists in pharmaceutical industries in India. To survive in society as a professional, the pharmacist will have to f...